

## Trobix Bio Receives Patent Allowance in Japan

Netanya, Israel, April 19, 2021

Netanya, Israel. Trobix Innovation Ltd. ([Trobix Bio](#)), an Israeli-based biotechnology company developing precision microbiome-based therapies to remove the threat of antimicrobial resistance, announces that it has received from the Japanese Patent Office (JPO) a Notice of Allowance in Japan for its licensed patent application 2017-528575 titled “targeted elimination of bacterial genes”. The allowed patent application covers methods of using CRISPR technology to sensitize bacteria to antibiotics and select for the sensitized bacteria.

“We are excited to receive our first patent allowance for this key patent family”, said Dr. Adi Elkeles, Founder & CEO of Trobix Bio. “The claims granted by the JPO provide Trobix Bio with broad-based protection in Japan, a very important jurisdiction to hold a patent coverage and an important target market where our lead investors are located”, he added.

### **About Trobix Bio**

Trobix Bio is a biotechnology company whose vision is to develop products that engineer the human microbiome and address critical unmet needs such as the threat of antimicrobial resistance. The company is leveraging its platform ActiSense™ CRISPR and GoTrap™ delivery technologies to develop phage-based products that can effectively deliver DNA to a wide range of bacterial pathogens and actively sensitize these pathogens to antibiotics. The company’s lead product, TBX101, targets patients carrying gut antimicrobial resistant bacteria, resulting in an antibiotic sensitive gut microbiome.

### **For more information, please contact:**

**Dr. Adi Elkeles**

CEO & co-Founder

Trobix Bio

Tel: +972-54-6402333

Email: [adie@trobixbio.com](mailto:adie@trobixbio.com)